• Fibrocell Science Inc., of Exton, Pa., said it submitted to the FDA its Phase II protocol for testing lead therapy azficel-T in improving the range of motion, function and flexibility in patients with existing restrictive burn scars. Azficel-T, an autologous cell therapy, previously gained approval as LaViv for reducing the appearance of moderate to severe nasolabial fold wrinkles.